RxDoctor Payments Data

Wendy Foster

Family · Plano, TXNPI 1003030297

Payments from drug & device makers

$6,701in general payments, 2019–2025

Across 199 payments — averaging $33.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Itamar Medical Inc$1K
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$776
  • Boston Scientific$594
  • Pfizer$574
  • Impulse Dynamics (USA) Inc.$528
  • Sanofi-aventis U.S. LLC$468
  • plus $3K from 21 others

What the payments were for

  • Consulting fees$2564%
  • Food & beverage$6,33795%
  • Education$1082%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,701 in reported general payments places this provider in the 95th percentile of 15,456 family providers in Texas.

See all family providers in Texas

Medicare billing

Part B allowed, 2024
$173,281
Medicare patients
1,038
Services billed
3,303

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban611$735,511
XareltoRivaroxaban180$206,584
MultaqDronedarone Hcl68$97,179
Dofetilide204$30,464
Flecainide Acetate405$16,706
Metoprolol Succinate483$7,789
Propafenone Hcl ErPropafenone Hcl24$6,526
Amiodarone Hcl222$5,373
Diltiazem 24hr Er (Cd)Diltiazem Hcl89$2,239
Propafenone Hcl35$2,126
SotalolSotalol Hcl73$1,592
Metoprolol Tartrate238$1,582
Carvedilol102$1,234
Diltiazem Hcl31$986
Digoxin36$665

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$574$735,511611 claims
Johnson & JohnsonXarelto$421$206,584180 claims
Sanofi-aventis U.S. LLCMultaq$468$97,17968 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 15,456 family providers in Texas.

Other family in Plano

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →